Literature DB >> 8725995

Didanosine measurement by radioimmunoassay.

M DeRemer1, R D'Ambrosio, G D Morse.   

Abstract

Didanosine is commonly prescribed as monotherapy or as part of a combination regimen for patients with human immunodeficiency virus infection. The use of lower doses, either as part of a combination regimen or as a result of dose reduction secondary to clinical intolerance, requires that a sensitive assay method be available for either traditional or population-based pharmacokinetic evaluations. We evaluated a radioimmunoassay technique with a standard curve range of 0 to 100 ng/ml in human plasma, urine, and cerebrospinal fluid and assessed its accuracy and precision for use in pharmacokinetic studies.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725995      PMCID: PMC163325          DOI: 10.1128/AAC.40.6.1331

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Quantitation of didanosine in human plasma and urine by high-performance liquid chromatography.

Authors:  C A Knupp; F A Stancato; E A Papp; R H Barbhaiya
Journal:  J Chromatogr       Date:  1990-11-30

2.  Clinical pharmacology of 2',3'-dideoxyinosine in human immunodeficiency virus-infected children.

Authors:  F M Balis; P A Pizzo; K M Butler; M E Hawkins; P Brouwers; R N Husson; F Jacobsen; S M Blaney; J Gress; P Jarosinski
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

3.  Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection.

Authors:  N R Hartman; R Yarchoan; J M Pluda; R V Thomas; K S Marczyk; S Broder; D G Johns
Journal:  Clin Pharmacol Ther       Date:  1990-05       Impact factor: 6.875

4.  Once-daily administration of 2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. Results of a Phase I trial.

Authors:  T P Cooley; L M Kunches; C A Saunders; J K Ritter; C J Perkins; C McLaren; R P McCaffrey; H A Liebman
Journal:  N Engl J Med       Date:  1990-05-10       Impact factor: 91.245

5.  2',3'-dideoxyinosine (ddI) in patients with the acquired immunodeficiency syndrome or AIDS-related complex. A phase I trial.

Authors:  J S Lambert; M Seidlin; R C Reichman; C S Plank; M Laverty; G D Morse; C Knupp; C McLaren; C Pettinelli; F T Valentine
Journal:  N Engl J Med       Date:  1990-05-10       Impact factor: 91.245

6.  Pharmacokinetics of zidovudine and dideoxyinosine alone and in combination in patients with the acquired immunodeficiency syndrome.

Authors:  M Barry; J L Howe; S Ormesher; D J Back; A M Breckenridge; C Bergin; F Mulcahy; N Beeching; F Nye
Journal:  Br J Clin Pharmacol       Date:  1994-05       Impact factor: 4.335

7.  Pharmacokinetics of didanosine in patients with acquired immunodeficiency syndrome or acquired immunodeficiency syndrome-related complex.

Authors:  C A Knupp; W C Shyu; R Dolin; F T Valentine; C McLaren; R R Martin; K A Pittman; R H Barbhaiya
Journal:  Clin Pharmacol Ther       Date:  1991-05       Impact factor: 6.875

8.  Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection.

Authors:  A C Collier; R W Coombs; M A Fischl; P R Skolnik; D Northfelt; P Boutin; C J Hooper; L D Kaplan; P A Volberding; L G Davis; D R Henrard; S Weller; L Corey
Journal:  Ann Intern Med       Date:  1993-10-15       Impact factor: 25.391

9.  Impact of bioavailability on determination of the maximal tolerated dose of 2',3'-dideoxyinosine in phase I trials.

Authors:  G L Drusano; G J Yuen; G Morse; T P Cooley; M Seidlin; J S Lambert; H A Liebman; F T Valentine; R Dolin
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

10.  A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.

Authors:  R Yarchoan; J A Lietzau; B Y Nguyen; O W Brawley; J M Pluda; M W Saville; K M Wyvill; S M Steinberg; R Agbaria; H Mitsuya
Journal:  J Infect Dis       Date:  1994-01       Impact factor: 5.226

View more
  5 in total

1.  Relationship between didanosine exposure and surrogate marker response in human immunodeficiency virus-infected outpatients.

Authors:  J M Adams; M J Shelton; R G Hewitt; T H Grasela; M DeRemer; G D Morse
Journal:  Antimicrob Agents Chemother       Date:  1998-04       Impact factor: 5.191

2.  Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection.

Authors:  G D Morse; M A Fischl; M J Shelton; S R Cox; M Driver; M DeRemer; W W Freimuth
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 3.  Antiretroviral bioanalysis methods of tissues and body biofluids.

Authors:  Robin DiFrancesco; Getrude Maduke; Rutva Patel; Charlene R Taylor; Gene D Morse
Journal:  Bioanalysis       Date:  2013-02       Impact factor: 2.681

4.  Multiple-Dose Pharmacokinetics of Delavirdine Mesylate and Didanosine in HIV-Infected Patients.

Authors:  Gene D Morse; Susan E Cohn; Mark J Shelton; Carol Greisberger; Steven R Cox; Andrew A Della-Coletta; William W Freimuth; Richard C Reichman
Journal:  Clin Drug Investig       Date:  2003       Impact factor: 2.859

5.  Determination of ddATP levels in human immunodeficiency virus-infected patients treated with dideoxyinosine.

Authors:  Cecile Le Saint; Raphael Terreux; Daniele Duval; Jacques Durant; Helene Ettesse; Pierre Dellamonica; Roger Guedj; Jean Pierre Vincent; Anny Cupo
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.